Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

ChimeriVax-JE. Acambis.

¹ID Biomedical Corp, 7150 Frederick Banting, Ville St-Laurent, Quebec H4S 2A1, Canada. tjones@idbiomedical.com

Current Opinion in Investigational Drugs (London, England : 2000)

|September 26, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.

Vaccine·2012

Same author

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.

PloS one·2010

Same author

Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.

Current opinion in investigational drugs (London, England : 2000)·2010

Same author

GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.

Current opinion in molecular therapeutics·2009

Same author

IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection.

Current opinion in molecular therapeutics·2009

Same author

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Current opinion in molecular therapeutics·2008

Acambis is developing the ChimeriVax-JE vaccine for Japanese encephalitis (JE) prevention. Phase II trials were completed by February 2002, with further studies initiated in children and Australia by May 2003.

Area of Science:

Virology
Vaccinology
Immunology

Background:

Japanese encephalitis (JE) is a significant public health concern in endemic regions.
Effective prophylaxis against JE virus infection is crucial for disease control.

Purpose of the Study:

To evaluate the safety and immunogenicity of the ChimeriVax-JE vaccine.
To advance the development of a novel JE vaccine candidate.

Main Methods:

Initiation and progression of Phase II clinical trials for the ChimeriVax-JE vaccine.
Studies conducted in various populations including children in endemic areas and Australia.

Main Results:

Completion of initial Phase II studies by February 2002.

Related Experiment Videos

Commencement of further Phase II trials by May 2003, indicating ongoing development and evaluation.

Conclusions:

The ChimeriVax-JE vaccine is under active clinical development.
Ongoing trials aim to establish the vaccine's efficacy and safety profile for JE prophylaxis.